Wave Life Sciences Announces First-Ever Therapeutic RNA Editing …
Wave expects to share multidose data from the RestorAATion-2 trial in 2025. Annual Research Day on October 30 th will highlight WVE-006 proof-of-mechanism data and Wave’s new wholly owned GalNAc-RNA editing programs, in addition to an obesity program update with new preclinical data for WVE-007 (INHBE GalNAc-siRNA)
Wave sees RNA editing validation in early trial results
2 days ago · Clinical trial results released by Wave Life Sciences Wednesday appear to provide early validation for the company’s newest drugmaking technology as well as a burgeoning field of genetic medicine, RNA editing. The data are from just two patients, the first treated in a Wave study of the biotechnology firm’s medicine for an inherited lung ...
Wave Clinical Trial Shows First Successful RNA Editing in Humans
1 day ago · News of the human RNA editing proof-of-concept sent Wave’s shares skyrocketing 74% today to $14.90 from yesterday’s close of $8.56. ... Wave is expected to reveal its next RNA targets at its ...
Wave hails human RNA editing first for GSK-partnered prospect
1 day ago · Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA editing in humans. The update on the GSK-partnered prospect sent Wave’s ...
RNA-Editing Stocks Soar on Wave Life’s Breakthrough Trial Data
1 day ago · Wave Life Sciences Ltd. said it achieved so-called proof-of- mechanism in a single-dose trial of its potential treatment for a genetic disorder that causes lung and liver diseases. Its stock ...
RNA-editing stocks soar on Wave Life’s breakthrough trial data
1 day ago · Companies developing RNA-editing therapies are rallying Wednesday after breakthrough data from a clinical trial showed the technology’s promise as a treatment. Wave Life Sciences Ltd. said it ...
Shoot the messenger: RNA editing is here - Nature Biotechnology
Mar 6, 2023 · Wave is among a growing cluster of firms harnessing an endogenous enzyme, adenosine deaminase acting on RNA (ADAR), to edit mRNA transcripts. Interest in the area is exploding, as evidenced by...
Move over, CRISPR: RNA-editing therapies pick up steam - Nature
Feb 16, 2024 · Wave Life Sciences in Cambridge, Massachusetts, is exploring single-base editing to treat a genetic disorder called alpha-1 antitrypsin deficiency (AATD), which can damage the lungs and the...
RNA-editing drugs advance into clinical trials - Nature
Apr 18, 2024 · Wave Life Sciences advanced the first ADAR-based RNA editor into healthy volunteers in 2023 for the hereditary disorder alpha-1 antitrypsin deficiency (AATD). The company is set to start dosing...
GSK and Wave Life Sciences announce collaboration to drive …
Dec 13, 2022 · WVE-006 is a potential first-in-class RNA editing candidate (AIMer) and the most advanced program currently in development using an oligonucleotide to harness an endogenous enzyme for editing. Wave expects to submit clinical trial applications for WVE-006 in 2023. About Wave Life Sciences.
- Some results have been removed